Dance Biopharm, which is developing an insulin soft mist inhaler, has named Melissa Rhodes as Chief Development Officer and Michael Kaseta as its new Chief Financial Officer. The company said that former CFO Don Huffman will continue to act as an advisor.
Rhodes was most recently Chief Development Officer at Roivant’s Altavant Sciences and was previously Senior VP of Nonclinical Research at Roivant. Kaseta was most recently CFO of Aralez Pharmaceuticals and was previously VP and CFO of Global Services at Sanofi.
Dance Biopharm CEO Anne Whitaker commented, “We are excited to welcome Melissa and Mike to our rapidly growing executive team. Their track record of strong leadership and technical expertise provides Dance with the right infusion of industry experience and energy to advance the development of our inhaled biologics portfolio for treatment of patients living with chronic diseases.”
She added, “Melissa’s unique combination of experience working with both early and late stage products has prepared her well for leading the Phase 3 clinical development of Dance 501 and transition of our pipeline product research programs into successful clinical programs. Mike’s deep finance and diabetes specific experience will prove invaluable as we focus on executing on the Dance 501 registration trials, strengthening the company’s market profile and keeping Dance well-funded to support the advancement of our portfolio. I am delighted to have these two leaders join our team!”
Read the Dance Biopharm press release.
